

DAFTAR PUSTAKA

1. McMahon BJ. Natural history of chronic hepatitis B. *Clin Liver Dis.* 2010 August; 14(3): 381–96.
2. Lesmana RA, Lesmana LA. Hepatitis B di Indonesia dari molekuler sampai ke terapi Jakarta; 2015:1–100.
3. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD Guidelines for treatment of chronic hepatitis B. *HEPATOLOGY.* 2016 January; 63(1): 261–83.
4. Tram T, Tran. Hepatitis B in pregnancy. *CID.* 2016; 62(4): 314–7.
5. Gani RA, Hasan I, Djumhana A, Setiawan PB. Konsensus nasional penatalaksanaan hepatitis B di Indonesia 2012. editor: Akbar N. PPHI; 2012:1–45.
6. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. *Hepatology Int.* 2012; 6(3): 531–61.
7. Isogawa M, Tanaka Y. Immunobiology of hepatitis B virus infection. *Hepatology Research.* 2015; 45: 179–89.
8. Boesecke C, Wasmuth JC. Hepatitis B. In Stefan M, Berg T, Rockstroh J, Sarrazin C, editors. *Hepatology 2012.* 3rd ed.: Cologne: Flying Publisher; 2012: 32–43.
9. Lesmana CR, Hasan I, Gani RA, Sanityoso A, Setiawan PB, Djumhana A. Konsensus nasional penatalaksanaan hepatitis B di Indonesia 2017. editor: Lesmana CR. PPHI; Jakarta; 2017: 1–82.
10. Wibawa I, Primadharsini PP. Immunobiologi dan imunoterapi hepatitis B kronis. Div.Gastroentero-hepatologi, Dept.Ilm. Penyakit Dalam FK Unud/RSUP Sanglah Denpasar; 2017: 1–9.
11. Kondo Y, Kobayashi K, Asabe S, Shiina M, Niitsuma H, Ueno Y, et al. Vigorous response of cytotoxic T lymphocytes associated with systemic activation of CD8 T lymphocytes in fulminant hepatitis B. *Liver Int.* 2004; 24: 561–7.
12. Yang P, Althage A, Chung J, Maier H, Wieland S, Isogawa M, et al. Immune effectors

required for hepatitis B virus clearance. *Proc Natl Acad Sci USA*. 2010; 107: 798–802.

13. Boni C, Penna A, Ogg G. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. *Hepatology*. 2001; 33: 963–71.
14. Purnomo HD. Respon imun pada infeksi virus hepatitis B kronik. In *Surabaya Weekend Course*; Surabaya; 2016: 1–9.
15. Shimizu Y. T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. *World J Gastroenterol*. 2012; 18: 2443–51.
16. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. *Ann N Y Acad Sci*. 2011; 1217: 45–59.
17. Chen J, Wang XM, Wu XJ, Wang Y, Zhao H, Shen B, et al. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. *Inflamm Res*. 2011; 60 : 47–53.
18. Peng G, Luo B, Li J, Zhao D, Wu W, Chen F, et al. Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients. *J Clin Immunol*. 2011;31: 195–204.
19. Boni C, Fiscaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. *J Virol*. 2007;81: 4215–25.
20. Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. *J Hepatol*. 2014; 61: 1212–9.
21. Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. *HEPATOLOGY*. 2010; 48(3): 759–69.
22. Fiscaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. *Gastroenterology*. 2010;138: 682–93.
23. Tzeng HT, Tsai HF, Liao HJ, Lin YJ, Chen L, Chen PJ, et al. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. *PLoS ONE*. 2012 June; 7(6): 1–9.

24. Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV. CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. *PLoS Pathog.* 2013; 9(7): 1–16.
25. Liu J, Zhang E, Ma Z, Wu W, Kosinska A. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. *PLoS Pathog.* 2014; 10(1): 1–14.
26. Cheng HY, Kang PJ, Chuang YH, Wang YH. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. *Plos One.* 2014 November; 9(11): 1–15.
27. Liaw YF, Chu CM. Hepatitis B virus infection. *Lancet.* 2009; 373(9663):582-92. *Lancet.* 2009; 373(9663): 583–92.
28. Chan HL, Alex T, Peignoux MM, Piratvisuth T, Comberg M, Brunetto MR. Hepatitis B surface antigen quantification: Why and how to use it in 2011—a core group report. *J of Hepatology.* 2011; 30: 1–11.
29. Hadziyannis E. Quantification of HBsAg in serum: characteristic of the assay. *OA Hepatology.* 2013: 1–6.
30. Lee JM, Ahn SH. Quantification of HBsAg: Basic virology for clinical practice. *World J of Gastroenterol.* 2011; 17: 283–9.
31. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic Hepatitis B: new trick of old dog. *J Gastroenterol.* 2013; 48: 13–21.
32. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses : a global overview. *Clin Liver Dis.* 2010; 14(1): 1–21.
33. Shire NJ. Cure strategies for hepatitis B virus: The promise of immunotherapy. *The American College of Clinical Pharmacology.* 2017; 6(2): 186–94.
34. Jules L, Dienstag. Hepatitis B virus infection. *N Engl J Med.* 2008; 359: 1486–1500.
35. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. *J Clin Virol.* 2005; 34(1): 1–3.
36. WGO Practice Guideline Hepatitis B. In *World Gastroenterology Organisation*; 2008: 1–29.

37. Slederdissen CH, Conberg M. The role of HBsAg level in the current management of chronic HBV infection. *Annals of Gastroenterology*. 2014; 27: 1–8.
38. Martanne G, Zekry A. Natural history of chronic hepatitis B virus infection. Gastroenterology and Hepatology Department, St George hospital, Kongarah. 2009: 40–5.
39. You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. *World J Gastroenterol*. 2014 Oktober; 20(37): 13293–305.
40. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. *Hepatology*. 2009; 49: 1132–40.
41. Zhang JY, Zou ZS, Huang A, Zhang Z, Fu JL, Xu XS. Hyper-activated pro-inflammatory CD16 monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B. *PLoS One*. 2011; 6: e17484:24–33.
42. Chen MT, Billaud JN, Sallberg M, Guidotti LG, Chisari FV, Jones J. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. *Proc Natl Acad Sci USA*. 2004; 101: 14913–8.
43. Hakim MS, Spaan M, Harry L, Jansen A, Boonstra A. Inhibitory receptor molecules in chronic hepatitis B and C infections: novel targets for immunotherapy? *Rev. Med. Virol*. 2014; 24: 125–38.
44. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. *Gut*. 2012; 61: 1754–64.
45. Michel ML, Deng Q, Bourguine MM. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. *J Hepatol*. 2011; 54: 1286–96.
46. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adam WC. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. *J Exp Med*. 2006; 203: 2281–92.
47. Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. *Am J Pathol*. 2000; 156: 1117–32.
48. Schmidt J, Blum HE, Thimme R. Julia Schmidt, Hubert E Blum and Robert Thimme. T-cell responses in hepatitis B and C virus infection: similarities and differences.

Emerging Microbes and Infections. 2013; e15: 1–8.

49. Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. *Cell Death and Disease*. 2015; 6(42): 1–10.
50. Balmasova IP, Yushchuck ND, Mynbaev OA, Alla NR, Malova ES, Shi Z. Immunopathogenesis of chronic hepatitis B. *World J Gastroenterol*. 2014 October; 20(39):14516–71
51. Ferrari C. HBV and the immune response. *Liver Int*. 2015; 35(1): 121–8.
52. Luneman S, Malone DF, Hengst J. Compromised function of natural killer cells in acute and chronic viral hepatitis. *J Infect Dis*. 2014; 209: 1362–73.
53. Boni C, Laccabue D, Lampertico P. Restored function of HBV-specific T cells after long term effective therapy with nucleos(t)ide analogues. *Gastroenterology*. 2012; 143: 963–73.
54. Grimm D, Heeg M, Thimme R. Hepatitis B virus: from immunobiology to immunotherapy. *Clinical Science*. 2013; 124: 77–85.
55. Human IFN- γ High Sensitivity ELLISA BMS228HS: *eBioscience*; 2017:1–39.
56. Schroder K, Hertzog P, Ravasi T, Hume D. Interferon-gamma: an overview of signals, mechanism and functions. *J. Leukoc. Biol*. 2004; 75(2): 163–89.
57. Bonino F, Piratvisuth T, Brunetto MR, Liaw Y. Review Diagnostic markers of chronic hepatitis B infection and disease. 2010; 44: 35–44.
58. Tong S, Kim KH, Chante C, Wands J, Li J. Hepatitis B virus e antigen variants. *Int. J. Med. Sci*. 2005; 2(1): 2–7.
59. Rajbhandari R, Chung RT. Treatment of hepatitis B : a concise review. *The American College of Gastroenterology*. 2016 July; 7(10): 1–10.
60. Ma L, Cai YJ, Yu L, Feng JY, Wang J, Li C. Treatment with telbivudine positively regulates antiviral immune. *Antimicrobial Agents and Chemotherapy*. 2013; 57(3):1304–11
61. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. *Lancet Infect Dis*. 2012; 12: 341–53.
62. Bertoletti A, Rivino L. Hepatitis B: future curative. *Curr Opin Infect Dis*. 2014; 27:

528–34.

63. Loggi E, Vitale G, Conti F, Bernardi M, Andreone P. Chronic hepatitis B: Are we close to a cure? *Digestive and Liver Disease*. 2015; 47: 836–41.
64. Michel ML, Deng Q, Bourguine MM. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. *J Hepatol*. 2011; 54: 1286–96.
65. Koh S, Shimasaki N, Suwanarusk R. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. *Mol Ther Nucleic Acids*. 2013; 2: e114:1–9.
66. Forbi JC, Iperepolu OH, Zungwe T, Agwale SM. Prevalence of hepatitis B e antigen in chronic HBV carriers in north-central Nigeria. *J HEALTH POPUL NUTR*. 2012 Dec 30; 4: 377–82.
67. Khan F, Shams S, Qureshi ID, Israr M, Khan H, Sarwar MT. Hepatitis B virus infection among different sex and age groups in Pakistani Punjab. *Virology Journal*. 2011; 8(225): 1–5.
68. Chen P, Yu C, Wu W, Wang J, Ruan B, Ren J, et al. Serological profile among HBsAg-positive infection in southeast China: a community-based study. *Hepat Mon*. 2013; 13(1): 1–6.
69. Su WC, Hsieh TC, Hsieh TY, Tseng KC, Peng CY, Lin CL, et al. Younger age and female sex predict a better therapeutic response in HBeAg-positive chronic hepatitis B patients to entecavir therapy. *Advances in Digestive Medicine*. 2014; 1: 112–7.
70. Utama A, Siburian MD, Purwantomo S, Intan MD, Kurniasih TS, Gani RA, et al. Association of core promoter mutations of hepatitis B virus and viral load is different in HBeAg(+) and HBeAg(-) patients. *World J Gastroenterol*. 2011; 17(6): 708–16.
71. Pribadi J, Gani RA, Syam AF, Lesmana CR, Bela B, Setiati s, et al. Pola mutasi resistensi terhadap analog nukleos(t)ida virus hepatitis B pada pengidap kronis yang belum mendapatkan terapi. In Tesis; Jakarta:Universitas Indonesia; 2013:1–65.
72. Syam S, Zubir N, Arnelis , Najirman. Pola mutasi resistensi virus hepatitis B terhadap analog nukleos(t)ida pada pasien hepatitis B kronis naive etnik minangkabau. In Tesis; Padang: Universitas Andalas; 2014: 1–75.
73. Trisnaningtyas RW, Sari CP, Setyaningrum N. Evaluasi terapi pada pasien hepatitis B di RSUP Dr. Sardjito Yogyakarta. *Jurnal Ilmiah Farmasi*. 2017 Jan; 1: 29–34.

74. Li N, Zhou Z, Li F, Sang J, Han Q, Lv Y, et al. Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phase and HCC from other clinical disease in CHB virus infection. *Oncotarget*. 2017; 8(28): 46020–33.
75. Bi C, Huang D, Jiang J, Wang H, Bian C, Tian Z. Changes of serum sPD-1 levels in HBsAg-positive CHB patients with entecavir treatment and correlation with curative effect. *Turkish Journal of Medical Sciences*. 2018; 48: 286–92.
76. Zhang WJ, Peng CH, Zheng SS. Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B. *Hepatobiliary Pancreat Dis Int*. 2013; 12(4): 394–9.
77. Zhang Z, Zhang JY, Wang LF, Wang FS. Immunopathogenesis and prognostic immune markers of Chronic hepatitis B virus infection. *Journal of Gastroenterology and Hepatology*. 2012; 27: 223–30.
78. Ying XD, Liang LB, Juan CF, Hong D, Tian CY, Hong ZX, et al. Programmed death-1 (PD-1) and PD-L 1 expression during antiviral treatment of chronic hepatitis B. *Chin J Hepatol*. 2010; 18(9):646–50.
79. Trehanpati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S, et al. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. *J Clin Immunol*. 2011 Februari; 31: 509–20.
80. Vanwolleghem T, Hou J, Oord GV, Andeweg AC, Osterhaus AD, Pas SD. Re-evaluation of Hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. *Hepatology*. 2015 July; 62(1): 87–100.
81. Rizvi M, Azam M, Ajmal MR, Malik A, Shukla I, Afroz N. Role of interferon-gamma and interleukin-12 in the immunopathogenesis of hepatitis B virus infection. *EJOHG*. 2012 January-June; 2(1): 5–9.
82. Schreiber GH, Scheiber RD. Interferon-gamma. In: Thomson AW, Lotze MT, editors. *The Cytokine Handbook*. 1. Fourth ed. California-USA: Academic Press-Elsevier; 2003: 567–602.
83. Wahyuniati N. Peran interferon-gamma pada infeksi. *JKS*. 2017 Agustus; 17(2): 126–32.

